HOME Top Market Reports Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing, Microarray, Transcription Mediated Amplification, Hybridization], Applications Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood Screening, Microbiology] Global Opportunities, Competitor Analysis & Forecasts to 2017

Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing, Microarray, Transcription Mediated Amplification, Hybridization], Applications Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood Screening, Microbiology] Global Opportunities, Competitor Analysis & Forecasts to 2017

By: marketsandmarkets.com
Publishing Date: October 2012
Report Code: MD 1296

Discount on Reports  

Enquiry Before Buying
 
purchase report
download pdf  request for customisation


Molecular diagnostics (MDx) is a new class of diagnostic tests that identify nucleic acids or proteins to test the status of a disease. These nucleic acids or proteins, which belong to individual patients or foreign organisms, help determine a specific therapy, or risk of developing a specific disease, or other health conditions. MDx is the fastest growing segment within the in-vitro diagnostic (IVD) space, driven by accuracy, high sensitivity, fast turnaround time, easy workflow, and cost-effective testing. Owing to these factors, the market crossed $4.8 billion in 2011, and is poised to grow at a CAGR of 9.1% in the next five years.

MDx involves instruments and reagents that leverage multiple technologies to identify genetic variations. The technologies utilized in molecular diagnostics include polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization (In-situ Hybridization & fluorescence in situ hybridization (FISH)), DNA Sequencing, next generation sequencing (NGS), microarrays, and others.

Molecular diagnostics has applications in infectious disease molecular testing, oncology, blood screening, genetic testing, DNA fingerprinting (e.g., paternity testing, forensic testing), microbiology, tissue typing, and food pathogen detection testing. The booming MDx areas are molecular tests for women’s health, oncology, and organ transplant testing.

North America dominated the market in 2011; the U.S. is the prime market for molecular diagnostics companies due to the availability of government funds, rising incidence of chronic diseases related to the aging population, and high awareness of pharmacogenomics/personalized medicine. In addition, major local companies have easy access to this market, which makes the U.S. the largest and most significant market for suppliers. Europe is still suffering from the economic downturn and the Eurozone crisis and it is predicted that customers will delay purchases of capital equipments; this is expected to hamper the growth of this market, albeit for a short term. The Asian market, however, shows greater opportunities with the highest CAGR due to increased purchasing power, an emerging mindset toward wellness, preventive medicine, and increased access to cutting-edge products and services.

Factors like increase in awareness and acceptance of personalized medicine, advancements in molecular techniques, and increasing investments in genomics & proteomics research will spur the molecular diagnostics market in the future. Yet, reimbursement issues for non-coded tests and complex regulatory framework will restrict the growth of this market.

Molecular diagnostic tools have a vast base of end-users, which includes hospital-based laboratories, reference laboratories, and others (physicians’ labs, research laboratories, other healthcare clinics, and government agencies). Hospitals offer the major chunk of business for MDx companies; however, reference laboratories are growing at a high CAGR and are driving the market, as they perform complex tests and offer expertise to small hospitals setups, clinical researchers, and insurance companies.

Although the market is fragmented with more than 500 companies, the most prominent players are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-Probe (U.S.), Qiagen (The Netherlands), Abbott Diagnostics (U.S.), Becton Dickinson (U.S.) and Cepheid (U.S.), to name a few.

Scope of the Report

This research report categorizes the global market into application, technology, and product type.  All these markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the devices market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia-Pacific, and Rest of the World) to provide in-depth information on the global scenario.

Global Market, By Application

  • Infectious Diseases
  • Oncology
  • Genetics
  • Blood Screening
  • Microbiology
  • Others

Global Market, By Technology

  • Polymerase chain reaction (PCR)
  • Transcription-mediated amplification (TMA)
  • Hybridization (In-situ hybridization & Fluorescent in situ hybridization (FISH))
  • DNA Sequencing & Next-generation Sequencing
  • Microarray
  • Others

Global Market, By Product Type

  • Instruments
  • Reagents
  • Services & Software

Global Market, By End-users

  • Reference Laboratory
  • Hospital Laboratory
  • Others

Market, By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • RoE (Rest of Europe)
  • Asia
    • Japan
    • India
    • China
    • RoA (Rest of Asia)
  • RoW (Rest of the World)
    • Latin America
    • Pacific
    • Middle East & Africa

Each section of the report also provides market trends with respect to drivers, restraints, and opportunities. The report includes 21 company profiles and its competitive landscape section sketches the strategic developments in the market.

TABLE OF CONTENTS   
   
1 INTRODUCTION 
 
  1.1 KEY TAKE-AWAYS  
  1.2 REPORT DESCRIPTION  
  1.3 MARKETS COVERED  
  1.4 STAKEHOLDERS  
  1.5 RESEARCH METHODOLOGY  
      1.5.1 MARKET SIZE  
      1.5.2 MARKET SHARE  
      1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES  
      1.5.4 ASSUMPTIONS  
   
2 EXECUTIVE SUMMARY  
   
3 MARKET OVERVIEW  

  3.1 INTRODUCTION  
  3.2 MARKET SEGMENTATION  
  3.3 MARKET DYNAMICS  
      3.3.1 DRIVERS  
            3.3.1.1 Increasing awareness and acceptance of personalized medicine and companion diagnostics  
            3.3.1.2 Development of biomarker identification and advancements in molecular techniques  
            3.3.1.3 Proteomics and genomics technology research to goad molecular testing market  
            3.3.1.4 Increase in aging population demands growth of molecular diagnostics  
      3.3.2 RESTRAINTS  
            3.3.2.1 Increased cost with new & complex platforms demand skilled labor & mandatory training  
            3.3.2.2 Reimbursement issues  
            3.3.2.3 Complex regulatory framework to delay approvals of new molecular diagnostic tests  
      3.3.3 OPPORTUNITIES  
            3.3.3.1 Extending reach of molecular diagnostics  
            3.3.3.2 Emerging technologies can soon gain importance in molecular diagnostic tests  
  3.4 MARKET SHARE ANALYSIS  
  3.5 END-USER ANALYSIS  
  3.6 EFFECTS OF OBAMACARE ON THE MOLECULAR DIAGNOSTICS MARKET  
   
4 GLOBAL MARKET, BY APPLICATION  
  4.1 INTRODUCTION  
  4.2 INFECTIOUS DISEASES  
      4.2.1 HEPATITIS B VIRUS (HBV)  
      4.2.2 HEPATITIS C VIRUS (HCV)  
      4.2.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)  
      4.2.4 TUBERCULOSIS (TB)  
      4.2.5 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG)  
      4.2.6 HUMAN PAPILLOMAVIRUS (HPV)  
      4.2.7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)  
      4.2.8 OTHERS  
  4.3 ONCOLOGY  
      4.3.1 PROSTATE  
      4.3.2 BREAST  
      4.3.3 COLORECTAL  
      4.3.4 OTHERS  
  4.4 GENETICS  
  4.5 BLOOD SCREENING  
  4.6 MICROBIOLOGY  
  4.7 OTHERS  
   
5 GLOBAL MARKET, BY TECHNOLOGY  
  5.1 INTRODUCTION  
  5.2 POLYMERASE CHAIN REACTION (PCR)  
  5.3 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)  
  5.4 MICROARRAY  
  5.5 HYBRIDIZATION (IN SITU HYBRIDIZATION AND FLUORESCENCE IN SITU HYBRIDIZATION)  
  5.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING  
  5.7 OTHERS  
   
6 GLOBAL MARKET, BY PRODUCT TYPE  
  6.1 INTRODUCTION  
  6.2 INSTRUMENTS  
  6.3 REAGENTS  
  6.4 SERVICES  
   
7 GEOGRAPHIC ANALYSIS  
  7.1 INTRODUCTION  
  7.2 NORTH AMERICA  
      7.2.1 U.S.  
      7.2.2 CANADA  
  7.3 EUROPE  
      7.3.1 U.K.  
      7.3.2 GERMANY  
      7.3.3 FRANCE  
      7.3.4 ITALY  
      7.3.5 SPAIN  
      7.3.6 REST OF EUROPE  
  7.4 ASIA  
      7.4.1 JAPAN  
      7.4.2 INDIA  
      7.4.3 CHINA  
      7.4.4 REST OF ASIA  
  7.5 REST OF THE WORLD (ROW)  
      7.5.1 LATIN AMERICA  
      7.5.2 PACIFIC  
      7.5.3 MIDDLE EAST & AFRICA  
   
8 COMPETITIVE LANDSCAPE  
  8.1 INTRODUCTION  
  8.2 MERGERS & ACQUISTIONS  
  8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES  
  8.4 NEW PRODUCT LAUNCH  
  8.5 APPROVALS  
  8.6 EXPANSION  
  8.7 OTHERS  
   
9 COMPANY PROFILES  
  9.1 ABBOTT DIAGNOSTICS  
      9.1.1 OVERVIEW  
      9.1.2 FINANCIALS  
      9.1.3 PRODUCTS & SERVICES  
      9.1.4 STRATEGY  
      9.1.5 DEVELOPMENTS  
  9.2 BECKMAN COULTER, INC.  
      9.2.1 OVERVIEW  
      9.2.2 FINANCIALS  
      9.2.3 PRODUCTS & SERVICES  
      9.2.4 STRATEGY  
      9.2.5 DEVELOPMENTS  
  9.3 BECTON, DICKINSON & COMPANY  
      9.3.1 OVERVIEW  
      9.3.2 FINANCIALS  
      9.3.3 PRODUCTS & SERVICES  
      9.3.4 STRATEGY  
      9.3.5 DEVELOPMENTS  
  9.4 BIOCARTIS  
      9.4.1 OVERVIEW  
      9.4.2 FINANCIALS  
      9.4.3 PRODUCTS & SERVICES  
      9.4.4 STRATEGY  
      9.4.5 DEVELOPMENTS  
  9.5 BIOMERIEUX  
      9.5.1 OVERVIEW  
      9.5.2 FINANCIALS  
      9.5.3 PRODUCTS & SERVICES  
      9.5.4 STRATEGY  
      9.5.5 DEVELOPMENTS  
  9.6 CEPHEID  
      9.6.1 OVERVIEW  
      9.6.2 FINANCIALS  
      9.6.3 PRODUTS & SERVICES  
      9.6.4 STRATEGY  
      9.6.5 DEVELOPMENTS  
  9.7 EUROGENTEC SA  
      9.7.1 OVERVIEW  
      9.7.2 FINANCIALS  
      9.7.3 PRODUCTS & SERVICES  
      9.7.4 STRATEGY  
      9.7.5 DEVELOPMENTS  
  9.8 GENMARK DIAGNOSTICS  
      9.8.1 OVERVIEW  
      9.8.2 FINANCIALS  
      9.8.3 PRODUCTS & SERVICES  
      9.8.4 STRATEGY  
      9.8.5 DEVELOPMENTS  
  9.9 GENOMIC HEALTH, INC.  
      9.9.1 OVERVIEW  
      9.9.2 FINANCIALS  
      9.9.3 PRODUCTS & SERVICES  
      9.9.4 STRATEGY  
      9.9.5 DEVELOPMENTS  
  9.10 GEN-PROBE, INC. (HOLOGIC, INC.)  
      9.10.1 OVERVIEW  
      9.10.2 FINANCIALS  
      9.10.3 PRODUCTS & SERVICES  
      9.10.4 STRATEGY  
      9.10.5 DEVELOPMENTS  
  9.11 INNOGENETICS NV  
      9.11.1 OVERVIEW  
      9.11.2 FINANCIALS  
      9.11.3 PRODUCTS & SERVICES  
      9.11.4 STRATEGY  
      9.11.5 DEVELOPMENTS  
  9.12 INTELLIGENTMDX  
      9.12.1 OVERVIEW  
      9.12.2 FINANCIALS  
      9.12.3 PRODUCTS & SERVICES  
      9.12.4 STRATEGY  
      9.12.5 DEVELOPMENTS  
  9.13 LIFE TECHNOLOGIES CORPORATION  
      9.13.1 OVERVIEW  
      9.13.2 FINANCIALS  
      9.13.3 PRODUCTS & SERVICES  
      9.13.4 STRATEGY  
      9.13.5 DEVELOPMENTS  
  9.14 LUMINEX CORPORATION  
      9.14.1 OVERVIEW  
      9.14.2 FINANCIALS  
      9.14.3 PRODUCTS & SERVICES  
      9.14.4 STRATEGY  
      9.14.5 DEVELOPMENTS  
  9.15 MYRIAD GENETICS, INC.  
      9.15.1 OVERVIEW  
      9.15.2 FINANCIALS  
      9.15.3 PRODUCTS & SERVICES  
      9.15.4 STRATEGY  
      9.15.5 DEVELOPMENTS  
  9.16 NOVARTIS AG  
      9.16.1 OVERVIEW  
      9.16.2 FINANCIALS  
      9.16.3 PRODUCTS & SERVICES  
      9.16.4 STRATEGY  
      9.16.5 DEVELOPMENTS  
  9.17 QIAGEN  
      9.17.1 OVERVIEW  
      9.17.2 FINANCIALS  
      9.17.3 PRODUCTS & SERVICES  
      9.17.4 STRATEGY  
      9.17.5 DEVELOPMENTS  
  9.18 ROCHE DIAGNOSTICS  
      9.18.1 OVERVIEW  
      9.18.2 FINANCIALS  
      9.18.3 PRODUCTS & SERVICES  
      9.18.4 STRATEGY  
      9.18.5 DEVELOPMENTS  
  9.19 SEEGENE  
      9.19.1 OVERVIEW  
      9.19.2 FINANCIALS  
      9.19.3 PRODUCTS & SERVICES  
      9.19.4 STRATEGY  
      9.19.5 DEVELOPMENTS  
  9.20 SIEMENS HEALTHCARE  
      9.20.1 OVERVIEW  
      9.20.2 FINANCIALS  
      9.20.3 PRODUCTS & SERVICES  
      9.20.4 STRATEGY  
      9.20.5 DEVELOPMENTS  
    
   
LIST OF TABLES   
   
TABLE 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)  
TABLE 2 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY END-USERS, 2010 – 2017 ($MILLION)  
TABLE 3 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 4 GLOBAL INFECTIOUS DISEASES MDX MARKET, BY DISEASES, 2010 – 2017 ($MILLION)  
TABLE 5 INFECTIOUS DISEASES MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 6 GLOBAL ONCOLOGY MDX MARKET, BY TYPE, 2010 – 2017 ($MILLION)  
TABLE 7 ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 8 GENETICS MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 9 BLOOD SCREENING MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 10 MICROBIOLOGY MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 11 OTHER MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 12 GLOBAL MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 13 PCR TECHNOLOGY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 14 TMA TECHNOLOGY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 15 MICROARRAY TECHNOLOGY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 16 HYBRIDIZATION TECHNOLOGY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 17 DNA SEQUENCING & NGS MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 18 OTHER MOLECULAR DIAGNOSTICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 19 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 20 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 21 MOLECULAR DIAGNOSTIC REAGENTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 22 MOLECULAR DIAGNOSTIC SERVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)  
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)  
TABLE 24 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)  
TABLE 25 NORTH AMERICA: MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 26 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 27 NORTH AMERICA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 28 U.S.: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 29 U.S.: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 30 U.S.: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 31 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 32 CANADA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 33 CANADA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 34 EUROPE: MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)  
TABLE 35 EUROPE: MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 36 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 37 EUROPE: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 38 U.K.: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 39 U.K.: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 40 U.K.: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 41 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 42 GERMANY: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 43 GERMANY: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 44 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 45 FRANCE: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 46 FRANCE: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 47 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 48 ITALY: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 49 ITALY: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 50 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 51 SPAIN: MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)  
TABLE 52 SPAIN: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 53 REST OF EUROPE (ROE): MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 54 REST OF EUROPE (ROE):  MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 55 REST OF EUROPE (ROE):  MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 56 ASIA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)  
TABLE 57 ASIA: MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 58 ASIA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 59 ASIA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 60 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)  
TABLE 61 JAPAN: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 62 JAPAN: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 63 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 – 2017 ($MILLION)  
TABLE 64 INDIA: MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)  
TABLE 65 INDIA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 66 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 67 CHINA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 68 CHINA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 69 REST OF ASIA (ROA): MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 70 REST OF ASIA (ROA): MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 71 REST OF ASIA (ROA): MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 72 ROW: MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2010 - 2017 ($MILLION)  
TABLE 73 ROW: MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 74 ROW: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 75 ROW: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 76 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 77 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 78 LATIN AMERICA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 79 PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 80 PACIFIC: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 81 PACIFIC: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 82 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2010 - 2017 ($MILLION)  
TABLE 83 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
TABLE 84 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)  
TABLE 85 MERGERS & ACQUISTIONS, 2010 – 2012  
TABLE 86 AGREEMENTS, PARTNERSHIP, COLLABORATIONS, JOINT VENTURES, 2010 – 2012  
TABLE 87 NEW PRODUCT LAUNCH, 2010 – 2012  
TABLE 88 APPROVALS, 2010 – 2012  
TABLE 89 EXPANSION, 2011 – 2012  
TABLE 90 OTHERS, 2010 – 2012  
TABLE 91 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 92 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 93 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 94 BECKMAN COULTER, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2008 – 2010 ($MILLION)  
TABLE 95 BECKMAN COULTER, INC.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 96 BECKMAN COULTER, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 97 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 98 BECTON,DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 99 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 100 BIOMERIEUX: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 101 BIOMERIEUX: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 102 BIOMERIEUX: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 103 CEPHEID: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 104 CEPHEID: TOTAL REVENUE, BY SOURCE OF REVENUE, 2009 – 2011 ($MILLION)  
TABLE 105 CEPHEID: TOTAL PRODUCT SALES, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 106 CEPHEID: TOTAL PRODUCT SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 107 GENMARK DIAGNOSTICS: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 108 GENOMIC HEALTH, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 109 GENOMIC HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 110 GEN-PROBE, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 111 GEN-PROBE, INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 112 GEN-PROBE, INC.: TOTAL PRODUCT REVENUE, BY TYPE, 2009 – 2011 ($MILLION)  
TABLE 113 GEN-PROBE, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 114 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 115 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 116 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY 2009 – 2011 ($MILLION)  
TABLE 117 LUMINEX CORPORATION TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 118 LUMINEX CORPORATION REVENUE BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 119 MYRIAD GENETICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 120 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)  
TABLE 121 NOVARTIS AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 122 NOVARTIS AG: TOTAL REVENUE, BY SEGMENTS/OPERATING DIVISION, 2009 – 2011 ($MILLION)  
TABLE 123 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 124 QIAGEN N.V. TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 125 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 126 ROCHE GROUP: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 127 ROCHE DIAGNOSTICS: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 128 ROCHE DIAGNOSTICS: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 129 SEEGENE: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 130 SEEGENE: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 131 SIEMENS: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)  
TABLE 132 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 133 SIEMENS: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
   
    
LIST OF FIGURES   
   
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)  
FIGURE 2 MARKET SEGMENTATION  
FIGURE 3 MOLECULAR DIAGNOSTICS MARKET- DRIVERS & RESTRAINTS  
FIGURE 4 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2011  
FIGURE 5 KEY GROWTH STRATEGIES, 2010 – 2012  

Molecular diagnostics (MDx) is a new class of diagnostic tests that identify nucleic acids or proteins to test the status of a disease. These identified nucleic acids or proteins belong to individual patients or foreign organisms that help to determine a specific therapy, or risk of developing a specific disease or other health conditions. MDx is the fastest growing segment within the IVD space driven by accuracy, high sensitivity, fast turnaround time, easy workflow and cost-effective testing. However reimbursement issues, delay in approvals of new molecular diagnostic tests are restraining the growth of this market.

The global  market is estimated to be $4.8 billion in the year 2012; North America is the largest market, followed by Europe, and Asia. Developed geographies like North America and Europe are likely to grow at low CAGRs. Advanced technologies and government funding and well-established biotechnology industries are driving these geographies. However, the economic slowdown and the Eurozone debt crisis are hindering the growth of these geographies, though not to a great extent. 

Growth in the Asian market, especially China and India, is likely to be propelled by rising chronic diseases, awareness about the use of molecular tests to control the spread of these diseases, rising disposable income, and focus of major players in this market. This market will grow at the highest CAGR from 2012 to 2017.

Key players in the molecular diagnostics market are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-Probe (U.S.), Qiagen (The Netherlands), Abbott Diagnostics (U.S.), Becton Dickinson (U.S.) and Cepheid (U.S.), to name a few.

Global Molecular Diagnostics Market Revenue, By Technology, 2010 - 2017 ($Million)

Molecular Diagnostics Market

Source: Annual Reports, SEC Filings, Molecular Diagnostics Association, WHO, European Diagnostic Manufacturers Association, Expert Interviews, MnM Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports